6533b873fe1ef96bd12d4ce8

RESEARCH PRODUCT

Targeting cancer with peptide aptamers

Jessica GobboCarmen GarridoPierre ColasRenaud Seigneuric

subject

Cancer chemotherapyAptamermedicine.medical_treatmentRecombinant Fusion ProteinsPeptide Aptamersheat shock proteinAntineoplastic AgentsComputational biologyPharmacologyBiologyTargeted therapy03 medical and health sciences0302 clinical medicineNeoplasmsmedicineHumansNanotechnologyMolecular Targeted TherapyHeat-Shock Proteins030304 developmental biologyCancer0303 health sciencesClinical Trials as TopicCanceraptamerAntineoplastic Protocolsmedicine.diseasetargeted therapypeptide3. Good healthOncology030220 oncology & carcinogenesisResearch PerspectivesAptamers Peptide

description

Renaud Seigneuric 1,2 , Jessica Gobbo 1,2 , Pierre Colas 3 , Carmen Garrido 1,2 1 Heat Shock Proteins and Cancer, INSERM, UMR 866 IFR 100, Faculty of Medicine, 7 Boulevard Jeanne D'Arc, 21000 Dijon, France 2 Universite de Bourgogne, Dijon, France 3 CNRS USR 3151, P2I2 Group, Station Biologique, Roscoff, Bretagne, France Received: June 22, 2011; Accepted: June 24, 2011; Published: June 24, 2011; Correspondence: Renaud Seigneuric, email: // // Abstract A major endeavour in cancer chemotherapy is to develop agents that specifically target a biomolecule of interest. There are two main classes of targeting agents: small molecules and biologics. Among biologics (e.g.: antibodies), DNA, RNA but also peptide aptamers are relatively recent agents. Peptide aptamers are seldom described but represent attractive agents that can inhibit a growing panel of oncotargets including Heat Shock Proteins. Potential pitfalls and coming challenges towards successful clinical trials are presented such as optimizing the delivery of peptide aptamers thanks to Nanotechnology.

yearjournalcountryeditionlanguage
2011-06-24Oncotarget
http://europepmc.org/articles/PMC3248178